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Case RepoRt
A 73-year-old woman with no previous ocular history presented with 
one month of decreased vision in her right eye (OD). Her past medical 
history included atrial fibrillation, heart failure NYHA III, and controlled 
hypertension. Her current medications were Losartan 100 mg q.d., 
Xarelto 5 mg q.d., and Amiodarone 200 mg t.i.d. for the past 6 months. 
The patient underwent ophthalmologic examination, including Best-
Corrected Visual Acuity (BCVA), Ishihara pseudoisochromatic colour 
vision plate testing, and slit-lamp examination, including Intra-Ocular 
Pressure (IOP) with Goldman tonometry, and fundoscopy. The BCVA 
in the OD was counting fingers, and 20/20 in the left eye (OS). The 
patient could not distinguish the colour test plates with OD and 
showed a Relative Afferent Pupillary Defect (RAPD); OS normal. 
Slit-lamp examination revealed cornea verticillata, normal IOP and 
shallow anterior chamber in both eyes. Fundus examination revealed 
hyperaemic and swollen optic disc with haemorrhages in the OD and 
cup-disc ratio of 0.30 in the OS [Table/Fig-1].
Goldmann Perimeter (940; Haag-Streit AG, Liebefeld Switzerland) 
showed marked central scotoma in the OD [Table/Fig-1]; OS 
was normal. Optic coherence tomography (OCT; Stratus-OCT™, 
Carl-Zeiss Medictec, Inc., Dublin, CA) of the optic nerve showed 
increased RNFL average in the OD with 188 µm and 77 µm in the 
OS [Table/Fig-2]. The erythrocyte sedimentation rate was normal. A 
diagnosis of unilateral amiodarone-associated optic neuropathy in 
OD was made, and the cardiologist discontinued the medication. 
After 6 months the BCVA in OD improved to 20/400, the RAPD 
persisted, and the Goldmann perimetry showed an inferior altitudinal 
defect. Fundoscopic examination of the OD showed resolution of 
optic disc oedema and a pale colour of the optic nerve [Table/Fig-3], 
and the RNFL average was 40 µm [Table/Fig-2]; OS remained 
normal.
DisCussion
Amiodarone toxicity can involve many organs and tissues including 
lungs, thyroid, skin, nervous system, liver, and eye. Ocular toxicity 
includes corneal micro deposits (90%), halo vision (<5%), and optic 
neuropathy (0.0009% to 2%), and may appear on average 6.5 
weeks to 6 months after starting the drug at a daily dose of 200 mg 
[1-6]. Almost 30% of amiodarone-associated optic neuropathies 
have clinical features similar to Nonarteritic Anterior Ischemic Optic 
Neuropathy (NAION) [6].
In our patient it is difficult to distinguish between amiodarone toxicity 
and NAION because of her past medical history of atrial fibrillation, 
heart failure, and hypertension. Macaluso et al., proposed clinical 
features to distinguish amiodarone-associated optic neuropathy from 
NAION on the basis that insidious onset (months), visual acuity from 
20/20 to 20/200, bilateral ocular involvement, and resolution of disc 
oedema in months are often characteristics present with the use of 
amiodarone [7]. On the other hand, NAION typically present with a rapid 
onset (days to weeks), visual acuity of 20/20 to no light perception, 
resolution of disc oedema in weeks, and bilateral involvement (rarely 
simultaneous) [7]. Years later, Purvin et al., expanded this features 
and divided patients in groups of unilateral or bilateral disc oedema 
with typical or atypical features of NAION [8]. Atypical features being 
insidious onset of symptoms, mild optic nerve dysfunction, and 
generous cup–disc ratio in the fellow eye [8]. The presence of atypical 
features supports the association with amiodarone. Furthermore 
Passman et al. reported criteria for diagnosing optic neuropathy, the 
association with amiodarone, and the level of diagnostic certainty 
[9] [Table/Fig-4]. According to the ophthalmic features presented by 
Macaluso et al., Purvin et al., and Passman et al., our patient has an 
optic neuropathy associated with amiodarone. 
The prognosis of this type of neuropathy is very diverse. Passman 
et al., reported improvement in visual acuity in 58% [9] while 
Kervinen et al., reported permanent visual loss [2]. Six months after 
discontinuing amiodarone our patient’s right Goldman perimetry 
improved from central scotoma to inferior altitudinal defect, and 
her BCVA in the OD improved from counting fingers at 1 meter to 
20/400. 
In an effort to explain the pathophysiology of the disease Purvin et 
al., and Mansour et al., reported multiple lamellar inclusion bodies 
within large axons of the optic nerve without axonal loss [8,10]. In 
contrast to the absence of axonal loss in amiodarone toxicity Sühs et 
al., studying demyelinating optic neuritis, showed that RNFL thinned 
to levels greater than 10 µm below the healthy eye after a transient 
oedema that resolved within the first two months after disease onset 
[11].  Similar to Sühs et al., our patient’s RNFL showed an important 
elevation at baseline that returned to normal values after one month. 
Subsequently 2 months after discontinuation of the drug the RNFL 
reached 44 µm and remained almost at the same thickness until the 
last examination at 6 months. During the 6 months follow-up the 
RNFL decreased 148 µm [Table/Fig-2].
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A 73-year-old woman with atrial fibrillation treated with Amiodarone presented with Optic Disc oedema in right eye (OD). Using Optical Coherence 
Tomography (OCT) we describe the impact of this neuropathy on Retinal Nerve Fibre Layer (RNFL). At diagnosis RNFL average was of 188 
µm OD and 77 µm in the left eye (OS), six months after discontinuation of the drug decreased to 40 µm in OD and 76 µm in OS. The RNFL 
average of OD presented a transient increase during the acute oedema that returned to normal levels during the first month after discontinuation 
of the drug and fell dramatically to 44 µm at the second month and 40 µm at the sixth month. We show there is axonal loss after amiodarone-
associated optic neuropathy measured with OCT. The OCT may be used in these patients to document changes in RNFL in the follow-up.
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[table/fig-1]: Right Optic nerve at moment of diagnosis of right optic 
neuropathy associated with amiodarone. A OCT: oedema, B: Photograph 
of disc oedema, and C: Goldman perimetry: right central scotoma
right
eye
left
eye
difference
Od vs OS
RNFL Average (absolute values, µm)
Baseline 188 77 +111
1 month after discontinuation of amiodarone 72 76 -4
2 month after discontinuation of amiodarone 44 79 -35
4 month after discontinuation of amiodarone 41 74 -33
6 months after discontinuation of amiodarone 40 76 -36
[table/fig-2]: Right optic nerve 6 month post discontinuation of 
amiodarone. A: OCT: decreased RNFL fibre, B: photograph of optic nerve 
head atrophy and C:Goldman perimetry: inferior altitudinal defect
Van Elmbt et al., reported axonal loss and optic nerve atrophy 
after resolution of amiodarone-associated optic neuropathy with 
OCT [12]. However, the behaviour of RNFL through out the entire 
episode of oedema was not described. With this case, we show the 
variations of RNFL during and after amiodarone-associated optic 
neuropathy. We show there is transient elevation in RNFL during the 
first month with subsequent axonal loss. We recommend follow-
up visits every year with an ophthalmologist for screening patients 
using amiodarone. During this examinations, OCT of the optic nerve 
may be performed to document oedema or thinning in RNFL.
data elements Scoring (based on number of 
elements reported)
Optic 
neuropathy 
diagnosis (1 
point for each 
element)
Optic disc oedema, 
visual field defect, color 
vision abnormalities, optic 
disc atrophy, optic disc 
haemorrhages, afferent 
pupillary defect, intracranial 
hypertension, and change in 
visual acuity/subjective blurring 
of vision
Complete (6-8)
Partially complete (3-5)
Incomplete (<3)
Association 
with 
amiodarone 
(1 point for 
each element)
Dose, duration of treatment, 
duration of treatment 
before presentation, other 
simultaneous drug therapy, 
outcome post- discontinuation, 
change in visual acuity after 
initiation of amiodarone
Complete (5-6)
Partially complete (3-4)
Incomplete (<3)
Diagnostic 
certainty
Completeness of information 
provided and the diagnosis 
given by the reporting 
physician 
Probable (patient was diagnosed 
with optic neuropathy/neuritis) 
Possible (patient had one or 
more features suggestive of optic 
neuropathy/neuritis) 
Incomplete (no information is 
present on the final diagnosis 
or the presence or absence 
of features suggestive of optic 
neuropathy /neuritis)
[table/fig-4]: Passman et al., criteria for completeness of reporting for 
possible amiodarone-associated optic neuropathy cases
[table/fig-3]: Right optic nerve 6 month post discontinuation of 
amiodarone. A: OCT: decreased RNFL B: Photograph of optic nerve 
head atrophy and C: Goldman perimetry: inferior altitudinal defect
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